#United States #San Diego #Breast Cancer #Biotheryx #BTX-9341

Biotheryx's Landmark Phase 1 Study on BTX-9341

In a significant advancement for cancer treatment, Biotheryx, Inc., a pioneering biopharmaceutical company, recently announced findings from its Phase 1 Dose Escalation study of BTX-9341. Designed as a potent and selective CDK4/6 degrader, BTX-9341 aims to improve outcomes for patients suffering from advanced or metastatic HR+/HER2- breast cancer who have previously undergone CDK4/6 inhibitor therapy. This novel treatment promises to offer new hope for a heavily pretreated demographic with limited options due to drug resistance.

Study Overview

Conducted primarily at multiple sites across the United States, the Phase 1 clinical trial investigates BTX-9341 as a monotherapy and in conjunction with fulvestrant. Early results are encouraging, highlighting a favorable safety profile without the common toxicities associated with traditional CDK4/6 inhibitors, such as gastrointestinal distress or hepatotoxicity. Dr. Rachel M. Layman from The University of Texas MD Anderson Cancer Center emphasized this promise, stating that BTX-9341 has shown clinical activity in a patient population that typically experiences limited treatment options after multiple lines of therapy.

Key Findings

The trial's data exhibits several pivotal results. Prominent among them is a noteworthy clinical activity rate, showcasing prolonged partial responses and stable disease over what could be a protracted treatment timeline, extending to over 12 cycles for some participants.

1. Safety Profile: The study had no reports of serious adverse events, indicating BTX-9341's tolerability across participants (N=28). Observed hematologic events were transient and manageable, with no elevated grades of non-hematologic issues.
2. Dosage and Pharmacokinetics: Favorable pharmacokinetics suggest appropriate dosing schedules are possible, supporting a once-daily administration.
3. Clinical Activity: The data showcases a Clinical Benefit Rate (CBR) of 41.7% in treatment-evaluable participants. With about 40% having received chemotherapy and a substantial percentage undergoing previous targeted therapies (PI3K/AKT/mTOR), the results underline BTX-9341's potential effectiveness post-CDK4/6 inhibition.
4. Mechanism of Action: Biotheryx's unique approach of degrading CDK4/6 while inhibiting CDK2 transcription addresses several resistance mechanisms and may redefine strategies for treating this particularly challenging breast cancer subset.

Ongoing Developments

As of May 6, 2026, the Phase 1 Dose Expansion segment is also progressing, focusing on corroborating the efficacy and tolerability of BTX-9341 combined with fulvestrant. Future plans include enrolling up to 78 participants in this arm of the trial, with an eye towards measuring overall response rates and progression-free survival, critical indicators for treatment success.

Dr. Leah Fung, CEO of Biotheryx, noted, "These findings underscore our commitment to advancing BTX-9341 through its next clinical phases, potentially offering an invaluable avenue for patients grappling with limited treatment options following prior CDK4/6 therapies."

About Biotheryx

Biotheryx is at the forefront of biopharmaceutical innovation, focusing on developing a robust portfolio of protein degraders, exemplified by BTX-9341. This approach could lead to breakthroughs in oncology and inflammatory disease treatment, enhancing patients' quality of life and clinical outcomes. Founded on the principles of exploring novel mechanisms of action, Biotheryx leverages its proprietary PRODEGY platform, aiming to fill significant gaps in current cancer therapies, particularly for those deemed untargetable.

In conclusion, the promising data from Biotheryx's trial signals a potential paradigm shift in treating advanced HR+/HER2- breast cancer. As the study moves forward, the insights gleaned may pave the way for a new standard of care, aligning with the mission to combat cancer more effectively.

For more insights about Biotheryx and ongoing clinical advancements, visit their official website and follow their updates on LinkedIn.